AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06474793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy Intervention Group-1
Description: For four weeks, once a day, 30 minutes before going to bed, a mixture of 3% chamomile and 3% lavender oil, diluted with 2% jojoba oil, is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the right and left nose for 4 minutes. It is the group that massages the edges of the hole with the index finger in circular movements from top to bottom, and then drops 2 ml of the oil mixture into the palm of the hand, rubs the hands mutually, and gently massages the edges of the ear with the index finger in circular movements from top to bottom behind the right and left ears for 4 minutes.
Study NCT06474793 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy Intervention Group-2
Description: For four weeks, once a day, 30 minutes before going to bed, 3% vetiver oil diluted with 2% jojoba oil is dropped into the palm of the palm of 2 ml, and after rubbing the hands together, rub the edges of the right and left nostrils from top to bottom with the index finger for four minutes. It is a group where massage is applied with a massager and then 2 ml of the oil mixture is dropped into the palm of the hand, the hands are rubbed mutually, and then a gentle massage is applied behind the right and left ears with circular movements from top to bottom for 4 minutes.
Study NCT06474793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aromatherapy Placebo Control Group
Description: For four weeks, once a day, 30 minutes before going to bed, 2 ml of jojoba oil is dropped into the palm of the hand and after rubbing the hands mutually, massage the edges of the right and left nostril with circular movements from top to bottom with the index finger for four minutes and apply jojoba oil to the palm again. It is a group in which 2 ml is dropped and the hands are rubbed together and then gently massaged behind the right and left ears with circular movements from top to bottom for 4 minutes.
Study NCT06014814 — intervention group
Intervention type: PROCEDURE
Intervention: Catheter ablation
Description: Catheter ablation of atrial fibrillation
Study NCT05847712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated work in the heat
Description: Participants perform a continuous moderate-intensity work bout (metabolic rate of \~200 W/m2) until core temperature reaches 38.0°C (equivalent to a 1°C increase in body core temperature above resting levels), which is immediately followed by intermittent work using a 3:1 work-rest allocation, starting with a 15 min rest break followed by a 45 min work bout for a total work duration of \~240 min. The work protocol is performed in the morning of day 1, and repeated in a post-lunch work period (i.e., afternoon of day 1) and on the morning of the next day (i.e., morning of day 2).
Study NCT05214846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education and counseling
Description: After obtaining informed consent, the data collection form, Hospital Anxiety Depression Scale (HADS) was applied to both groups by face to face interview. Immediately after the questionnaires were answered, individual education and counseling were giving by the nurse researcher to intervention group for 30 minutes. In addition, the education and counseling given to the participants by the researcher.The experimental group was given a telephone number where they could receive consultancy services for 12 hours a day. Pre-test was applied. One day later, the pregnant woman was called and encouraged to call for all her questions, and she was informed that she would be returned when she called.
Study NCT05602311 — intervention group
Intervention type: DRUG
Intervention: General anesthetic
Description: Monitoring the changes of brain functional connectivity and assess cognition in two groups after general anesthesia
Study NCT05271279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVV-01 Injection+IBR900 Cell Injection
Description: 2 dose gradients are used for the OVV-01 injection, and the total infusion dose of IBR900 cell injection is 4.0×10\^9 cells per cycle.~OVV-01 injection will be first administered at W1D1 and then at W4D1 followed by every 2 weeks as a treatment cycle, for a total of 6 doses; after the test in the high-dose group is completed, the investigator and sponsor will determine whether to adjust the dosing frequency of OVV-01 (such as once a week) based on the result evaluations. The IBR900 cell injection will be first administered at W1D3 and W1D5 for 2 infusions, and then at W4D3 and W4D5, followed by every 4 weeks as a cycle, for a total of 4 doses, and cell infusions will be conducted at W1, W4, W8 and W12, respectively.
Study NCT05898269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trendelenburg maneuver
Description: Bed tilting from the +13° position to the -13° position for 60 seconds. Evaluator: relative change in continuous cardiac index between baseline, and the highest value observed during the maneuver
Study NCT05898269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory occlusion test (EE OCC)
Description: End-expiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause
Study NCT05898269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: End-expiratory and end-inspiratory occlusion test (EI OCC)
Description: End-inspiratory pause performed on the ventilator, and maintained for 15 seconds.~Evaluator: relative change in continuous cardiac index between baseline, and the value observed in the last 5 seconds of the respiratory pause. The evaluator is calculated as the sum of the relative change in cardiac index observed during the end-expiratory pause and that of the end-inspiratory pause. Hence, for this test, the evaluator will be coupled with that of intervention 2 (end-expiratory occlusion test).
Study NCT05691283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: trans cranial direct current stimulation (tDCS)
Description: Three weeks of 20-minute tDCS stimulation
Study NCT05691283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Three weeks of sham stimulation
Study NCT06191731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biological samples collection
Description: Urine samples are collected before Gd-CAs injection, and between 0- and two-and-a-half-hour post-injection of Gd-CAs.
Study NCT04800523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroMonitor System
Description: Implantable device to wirelessly and without catheters monitor the neurogenic bladder on an ambulatory basis
Study NCT04716881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone 380 MG
Description: Vivitrol (naltrexone) 380 mg delivered intramuscularly every 28 days
Study NCT05758363 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Consumption of dietary supplement.
Description: Consumption of a dietary supplement rich in glutathione, selenium, zinc, vitamin D and EPA/DHA. 1 capsule per day of the dietary supplement with breakfast.
Study NCT05758363 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Consumption of control product
Description: Consumption of 1 capsule per day of control product of identical appearance with breakfast.
Study NCT05539690 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: * Step-by-step training (5 levels)~* 30 minute per training~* 3 times per week~* 4 weeks
Study NCT04739358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Subjects will receive tepotinib daily in cycles of 21-day duration. Subjects in the Combination Therapy arm will continue to receive their last tolerable dose of tyrosine kinase inhibitor (TKI) together with tepotinib.
Study NCT06351332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azenosertib
Description: WEE1 inhibitor, 25 or 100 mg tablet, taken orally per protocol.
Study NCT06351332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Platinum coordination compound, 5-, 15-, 45-, and 60-mL vials, via intravenous (into the vein) infusion per institutional standards.
Study NCT06351332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Humanized immunoglobulin G4 monoclonal antibody, 4-mL vials, via intravenous (into the vein) infusion per protocol.
Study NCT04354025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cytokine induced memory-like NK cells
Description: -The CIML NK cells (maximum dose capped at 10 x 106/kg, minimum dose allowed is 0.5 x 106/kg) will be infused on Day 0 without a filter or pump.
Study NCT04354025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: -Fludarabine (dose: 30 mg/m\^2 per dose) will be given daily beginning on Day -7 for a total of 5 doses administered as an IV infusion over 30 minutes.
Study NCT06249334 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body electrical stimulation
Description: The protocol with whole-body electrical stimulation will begin in the intensive care unit and will be completed in the inpatient unit. To stimulate all proposed muscle groups, self-adhesive electrodes will be positioned bilaterally on the quadriceps femoris, tibialis anterior, biceps brachii and lower rectus abdominis muscles. The frequency of 75 Hz will be adopted and the intensity will be adjusted to cause visible muscle contraction. The progression of the therapy protocol will occur throughout the sessions aiming to reach 20 minutes of therapy and 80 contractions.
Study NCT06249334 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine physical therapy
Description: The protocol will be based on knee and hip flexion and extension movements; hip adduction and abduction; flexion and extension of shoulders, elbows and wrists; shoulder abduction and adduction; respecting the range of each joint. Volunteers will also perform transfers from lying to sitting and standing positions. Respiratory conduct will be based on ventilation patterns, bronchial hygiene maneuvers and cough.
Study NCT06313983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022+AI
Description: hemay022：orally once daily，A 21-day cycle
Study NCT06313983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib+Capecitabine
Description: Take the pills according to the instructions
Study NCT04745104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1707
Description: SHR-1707 will be administered through IV infusion
Study NCT06548347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linperlisib
Description: Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles
Study NCT06548347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linperlisib
Description: Linperlisib at 80 mg orally once daily (QD) or 60mg orally once daily (QD) plus CHOP, placebo at 80mg or 60 mg orally once daily (QD) plus CHOP for 6 cycles
Study NCT06563232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FNA group
Description: Fine-needle-aspiration (22G EchoTip Ultra Echo-3-22)
Study NCT06563232 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adapt FNB group
Description: Fine-needle-biopsy (22G Adapt Aspiration)
Study NCT06563193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NERVE GROWTH FACTOR
Description: urinary neurotrophins
Study NCT05513196 — intervention group
Intervention type: PROCEDURE
Intervention: Erector spinae plane block (ESPB)
Description: Bilateral erector spinae plane block will be performed with 20 mL, 0.25% bupivacaine at T9 level preoperatively.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mouth cancer warning
Description: Participants will view messages about the risk of mouth cancer from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Throat cancer warning
Description: Participants will view messages about the risk of throat cancer from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Voice box (larynx) warning
Description: Participants will view messages about the risk of voice box (larynx) cancer from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Esophagus cancer warning
Description: Participants will view messages about the risk of esophagus cancer from alcohol consumption.
Study NCT05553210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FOREST+
Description: The intervention will be delivered as an internet-based stress recovery intervention consisting of six weekly modules: introduction, psychological detachment, distancing, mastery, control, and keeping the change alive. Each module consists of a psychoeducational and an exercise component. During the program, a therapist provides individual feedback on the completed exercises and can also be available on request.
Study NCT04745104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered through IV infusion
Study NCT04071470 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling
Description: Couples in the storytelling intervention will receive 3 storytelling sessions- the couple can include any family or friends who they feel could support them during their treatment. Stories will include stories of couples who are supportive, those who experience difficulties, and families who do/do not support their use of PrEP
Study NCT04071470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrEP
Description: Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
Study NCT04071470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP
Description: Patients at risk of HIV acquisition will be provided PrEP medications and counseling in ANC
Study NCT05500027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum test
Description: serum test of sCD58 and TGFbeta1
Study NCT04509830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hip strengthening
Description: resistance training for hip abductor, hip extensor, and hip external rotator
Study NCT04509830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quadriceps strengthening, stretch hamstring,cuff muscles
Description: multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch
Study NCT04509830 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quadriceps strengthening, stretch hamstring,cuff muscles
Description: multi-angle isometric quadriceps strengthening and hamstring and cuff self stretch
Study NCT05345093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ialuxid gel
Description: Ialuxid® Gel is intended for topical external use. It is formulated with the appearance of white to pale yellow coloured consistent gel.~Ialuxid® Gel will be used for 8 weeks, 2-3 times a day.
Study NCT04822636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based mental health navigation
Description: Family-based navigator intervention combined with mHealth practices to improve mental health treatment initiation and engagement
Study NCT04354025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: -Ara-C (dose: 2000mg/m\^2 per dose) will be given daily for a total of 5 doses administered as IV infusion over 3 hours, starting the same day as fludarabine.
Study NCT04354025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: -Filgrastim (dose: 5 mcg/kg per dose to a maximum of 300 mcg) will be given subcutaneously daily for a total of 5 doses starting the same day as fludarabine and ara-C.
Study NCT04354025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: -IL-2 will be administered subcutaneously at a dose of 1 million units/m2 every other day from Day 0 to Day +12 (7 doses total).
Study NCT04354025 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Leukapheresis
Description: -Donor only
Study NCT05770414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make the Connection® Online Program
Description: Make the Connection® (MTC) is an evidence-based parenting program offered by Strong Minds Strong Kids, Psychology Canada. Recently, the MTC program has been adapted to an online platform to help increase scalability and accessibility across Canada. The online modality is self-administered by caregivers and consist of 8 weekly, 15-minute modules.~MTC is an attachment-focused, evidence-informed, parent training program that is designed to support the development of positive parent-child relationships by teaching caregivers to understand their infant's cues. The overarching goal of the program is to enhance parental attitudes and cognitions towards their infants, which have been shown to be associated with sensitive parenting behaviour, and in turn, secure child attachment. Ultimately, by improving parenting skills and attitudes, the program seeks to support secure infant attachment.
Study NCT05980000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is administered at a dose of 10 mg/kg over 60 minutes.
Study NCT05980000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
Study NCT05980000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is administered at a flat dose of 200 mg over 30 minutes.
Study NCT05706467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive high-frequency oscillatory ventilation
Description: Non-invasive high-frequency oscillatory ventilation generates high-frequency pressure fluctuations in the airway caused by the opening and closing of a solenoid valve.
Study NCT05706467 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive continuous positive airway pressure ventilation
Description: Non-invasive positive airway pressure ventilation is carried out through non-invasive ventilator.
Study NCT06453551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 1
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study NCT06453551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 2
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study NCT06453551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 3
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study NCT06453551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 4
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study NCT06453551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 5
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study NCT06453551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 6
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study NCT06453551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 7
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study NCT06453551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRN501 - Dose 8
Description: Each cohort consists of 9 participants and includes a placebo group. 6 in the TRN501 group and 3 in the placebo group, a total of 9 participants, are randomly assigned in a double-blind fashion. To each participant, single dose of TRN501 or a placebo will be administered.
Study NCT04834986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with Lenvatinib
Description: Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84.~Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver cancer warning
Description: Participants will view messages about the risk of liver cancer from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Colon and rectum cancer warning
Description: Participants will view messages about the risk of colon and rectum cancer from alcohol consumption.